Comparison · NCT05966129-155d1fee
Acute Pain - Immediate PGx Testing (Modified Intent-to-treat, mITT) vs Acute Pain - Delayed PGx Testing (Modified Intent-to-treat, mITT): Participants With Drug-Gene Concordance
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Acute Pain - Immediate PGx Testing (Modified Intent-to-treat, mITT) vs Acute Pain - Delayed PGx Testing (Modified Intent-to-treat, mITT): Participants With Drug-Gene Concordance. Trial comparisons, record NCT05966129-155d1fee. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05966129-155d1fee
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.636 | 0.563 | 0.704 | wilson | |
| Risk in group 2 | 0.269 | 0.208 | 0.339 | wilson | |
| Risk difference, group 1 minus group 2 | 0.368 | 0.266 | 0.458 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.37 | 1.81 | 3.1 | log | |
| Odds ratio, group 1 over group 2 | 4.77 | 3.03 | 7.5 | log | |
Number needed to treat, for one more participant with the outcome on Acute Pain - Immediate PGx Testing (Modified Intent-to-treat, mITT) than on Acute Pain - Delayed PGx Testing (Modified Intent-to-treat, mITT) | 2.72 | 2.18 | 3.75 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Acute Pain - Immediate PGx Testing (Modified Intent-to-treat, mITT) | Immediate genetic testing of CYP2D6 and clinical decisions support for pain management prescribing to the healthcare provider~Pharmacogenetic testing: Genetic testing of CYP2D6 and CYP2C19~Clinical decisions support: Prescribing recommendations to the provider based on the pharmacogenetic testing results | 112 | 176 | OG000 |
| Group 2 | Acute Pain - Delayed PGx Testing (Modified Intent-to-treat, mITT) | Delayed genetic testing of CYP2D6 and return of results after the conclusion of the 6-month follow-up period~Pharmacogenetic testing: Genetic testing of CYP2D6 and CYP2C19 | 47 | 175 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Participants With Drug-Gene Concordance
- Description
Drug-Gene Concordance defined as an agreement between the Pharmacogenomics (PGx) Test and the prescribed opioids post surgery for pain management in participants who have a genotypic or pheno-converted CYP2D6 activity score ≤ 0.75
- Time frame
- Within 10 days post-surgery
- Population
- Modified intent to treat (mITT) population, consisting of participants who completed their surgery and have a genotypic or phenoconverted CYP2D6 activity score ≤ 0.75.
Source ClinicalTrials.gov
Trial
- Title
- A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Acute Pain Trial)
- NCT number
- NCT05966129
- Phases
- NA
- Conditions
- Acute Pain
- Interventions
- Pharmacogenetic testing, Clinical decisions support
- Lead sponsor
- Duke University
- Results first posted
- 2025-06-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05966129?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05966129-155d1fee